NURO News and Press, NeuroMetrix Inc. From 10/19/23

NeuroMetrix Inc. (NURO) is expected to report for Q1 2024

WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA). As a Proud Sponsor NeuroMetrix will support the NFA’s mission to provide education, support, and ad...

2023-07-27 14:16:09 ET NeuroMetrix Inc. (NURO) Q2 2023 Earnings Call Transcript July 27, 2023 08:00 AM ET Company Participants Thomas Higgins - Senior VP, CFO and Treasurer Shai Gozani - Founder, Chairman, CEO, President and Secretary Conference Call Participan...

2023-07-27 07:08:21 ET NeuroMetrix press release ( NASDAQ: NURO ): Q2 GAAP EPS of -$0.19. Revenue of $1.66M (-21.0% Y/Y). Shares +2.23% PM. For further details see: NeuroMetrix GAAP EPS of -$0.19, revenue of $1.66M

WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovati...

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on July 27, ...

2023-07-11 11:06:07 ET NeuroMetrix ( NASDAQ: NURO ) has announced expansion of its sales force to drive further adoption of Quell Fibromyalgia, which is the first and only medical device authorized by the U.S. FDA to help reduce the symptoms of fibromyalgia. This expa...

WOBURN, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell ® Fibromyalgia, which is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help r...

WOBURN, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people with diabetes. Ke and colleagues developed and validated an algorithm to predict progress...

2023-06-21 08:27:37 ET Greenpro Capital  ( GRNQ ) +12% . Chemomab Therapeutics  ( CMMB ) +14% Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023. PureCycle Technologies ( PCT ) +15% s...